Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Cold Capsules (Fufang Ganmao Jiaonang) is a multi-ingredient oral medication widely marketed in China for the symptomatic treatment of the common cold and influenza. The product is a generic combination typically consisting of acetaminophen (an analgesic and antipyretic), chlorpheniramine maleate (an antihistamine), caffeine (a central nervous system stimulant), and artificial bezoar (a traditional Chinese medicine component used for its purported antipyretic and sedative properties). The formulation is designed to alleviate symptoms such as fever, headache, nasal congestion, and sneezing. Dongri Pharmaceutical is one of the manufacturers of this product, offering it in at least two variants, which may differ in the inclusion of additional agents like amantadine hydrochloride. Acetaminophen works by inhibiting prostaglandin synthesis in the central nervous system, while chlorpheniramine competes with histamine for H1-receptor sites on effector cells. Caffeine is included to mitigate the drowsiness often caused by the antihistamine component.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + caffeine + chlorpheniramine + artificial bezoar.